{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:59:55Z","timestamp":1791475195113,"version":"4.3.4"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.maturitas.2023.107846","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T21:14:52Z","timestamp":1694553292000},"page":"107846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Sequential management of postmenopausal health and osteoporosis: An update"],"prefix":"10.1016","volume":"177","author":[{"given":"Joaquin","family":"Calaf-Alsina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Gua\u00f1abens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Jes\u00fas","family":"Cancelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camil","family":"Castelo-Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Larrainzar-Garijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Neyro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Nogues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Diez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2023.107846_bb0005","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.2 (Updated June 2017)","author":"Higgins","year":"2017"},{"key":"10.1016\/j.maturitas.2023.107846_bb0010","series-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses","author":"Wells","year":"2023"},{"key":"10.1016\/j.maturitas.2023.107846_bb0015","author":"OCEBM Levels of Evidence Working Group"},{"key":"10.1016\/j.maturitas.2023.107846_bb0020","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1080\/13697137.2022.2097865","article-title":"Effects of exercise on vasomotor symptoms in menopausal women: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2022","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.107846_bb0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/jech-2017-209887","article-title":"Dietary intake and age at natural menopause: results from the UK Women's Cohort Study","volume":"72","author":"Dunneram","year":"2018","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.maturitas.2023.107846_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2022.04.008","article-title":"Menopause, wellbeing and health: a care pathway from the European Menopause and Andropause Society","volume":"163","author":"Lambrinoudaki","year":"2022","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2023.107846_bb0035","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.3390\/nu12113342","article-title":"The effect of the mediterranean diet on metabolic health: a systematic review and meta-analysis of controlled trials in adults","volume":"12","author":"Papadaki","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.maturitas.2023.107846_bb0040","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.7326\/M21-3324","article-title":"Vitamin D deficiency increases mortality risk in the UK biobank: a nonlinear mendelian randomization study","volume":"175","author":"Sutherland","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0045","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s40520-022-02279-6","article-title":"Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group","volume":"34","author":"Chevalley","year":"2022","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10417","article-title":"Controversies in vitamin D: a statement from the Third International Conference","volume":"4","author":"Giustina","year":"2020","journal-title":"JBMR Plus"},{"key":"10.1016\/j.maturitas.2023.107846_bb0055","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1210\/jc.2006-1404","article-title":"Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials","volume":"92","author":"Boonen","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.107846_bb0060","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2202106","article-title":"Supplemental vitamin D and incident fractures in midlife and older adults","volume":"387","author":"LeBoff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0065","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.107846_bb0070","first-page":"302","article-title":"No increase in fractures after stopping hormone therapy: results from the women's health initiative","volume":"102","author":"Watts","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.107846_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.107846_bb0080","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMp1514242","article-title":"Menopause management\u2014getting clinical care back on track","volume":"374","author":"Manson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.maturitas.2023.107846_bb0090","doi-asserted-by":"crossref","first-page":"m3873","DOI":"10.1136\/bmj.m3873","article-title":"Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases","volume":"371","author":"Vinogradova","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2023.107846_bb0095","doi-asserted-by":"crossref","first-page":"o485","DOI":"10.1136\/bmj.o485","article-title":"Risk of breast cancer with HRT depends on therapy type and duration","volume":"376","author":"Saul","year":"2022","journal-title":"Bmj"},{"key":"10.1016\/j.maturitas.2023.107846_bb0100","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.107846_bb0105","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.metabol.2016.01.004","article-title":"The timing hypothesis: do coronary risks of menopausal hormone therapy vary by age or time since menopause onset?","volume":"65","author":"Bassuk","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.maturitas.2023.107846_bb0110","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00198-020-05497-8","article-title":"Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?","volume":"31","author":"Rozenberg","year":"2020","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2023.107846_bb0115","doi-asserted-by":"crossref","unstructured":"The 2022 hormone therapy position statement of The North American Menopause Society, Menopause 29 (2022) 767\u2013794. doi:10.1097\/gme.0000000000002028.","DOI":"10.1097\/GME.0000000000002028"},{"key":"10.1016\/j.maturitas.2023.107846_bb0120","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/jc.2014-3062","article-title":"Associations of menopausal vasomotor symptoms with fracture incidence","volume":"100","author":"Crandall","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.107846_bb0125","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1001\/jama.2022.18625","article-title":"Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: US preventive services task force recommendation statement","volume":"328","author":"US Preventive Services Task Force","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.107846_bb0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.maturitas.2019.01.014","article-title":"Menopause: women should not suffer in silence","volume":"124","author":"Rees","year":"2019","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2023.107846_bb0135","series-title":"Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs","first-page":"333","article-title":"The role of SERMs in the management of postmenopausal women","author":"i Alsina","year":"2006"},{"key":"10.1016\/j.maturitas.2023.107846_bb0140","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/13543784.2021.1893305","article-title":"Fezolinetant in the treatment of vasomotor symptoms associated with menopause","volume":"30","author":"Depypere","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.maturitas.2023.107846_bb0145","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.107846_bb0150","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0155","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.107846_bb0160","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/mol.111.072249","article-title":"The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor \u03b1 and cyclin D1","volume":"80","author":"Lewis-Wambi","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.maturitas.2023.107846_bb0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0170","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0175","doi-asserted-by":"crossref","first-page":"E189","DOI":"10.1210\/jc.2013-1707","article-title":"Effects of bazedoxifene\/conjugated estrogens on the endometrium and bone: a randomized trial","volume":"99","author":"Pinkerton","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.107846_bb0180","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study","volume":"20","author":"Siris","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0185","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14656566.2019.1615882","article-title":"Bazedoxifene for the treatment of osteoporosis","volume":"20","author":"Yavropoulou","year":"2019","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.maturitas.2023.107846_bb0190","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2017.14484","article-title":"Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO\/ASCO","volume":"147","author":"Meier","year":"2017","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.maturitas.2023.107846_bb0195","doi-asserted-by":"crossref","unstructured":"Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society, Menopause 28 (2021) 973\u2013997. doi:10.1097\/gme.0000000000001831.","DOI":"10.1097\/GME.0000000000001831"},{"key":"10.1016\/j.maturitas.2023.107846_bb0200","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005496","article-title":"The effect of sequential therapy for postmenopausal women with osteoporosis: a PRISMA-compliant meta-analysis of randomized controlled trials","volume":"95","author":"Lou","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.maturitas.2023.107846_bb0205","first-page":"5432751","article-title":"Raloxifene has no efficacy in reducing the high bone turnover and the risk of spontaneous vertebral fractures after denosumab discontinuation","volume":"2018","author":"Gonzalez-Rodriguez","year":"2018","journal-title":"Case Rep. Rheumatol."},{"key":"10.1016\/j.maturitas.2023.107846_bb0210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00223-022-00962-4","article-title":"Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis","volume":"111","author":"Hong","year":"2022","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.maturitas.2023.107846_bb0215","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","article-title":"Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis","volume":"19","author":"Adami","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2023.107846_bb0220","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","article-title":"Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial","volume":"20","author":"Deal","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0225","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2023.107846_bb0230","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.107846_bb0235","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","article-title":"Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis","volume":"322","author":"Storm","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0240","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American association of clinical endocrinologists\/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.maturitas.2023.107846_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2023.107846_bb0255","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.107846_bb0260","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the american society for bone and mineral research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0270","article-title":"Bisphosphonates and risk of cardiovascular events: a meta-analysis","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.maturitas.2023.107846_bb0275","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis","volume":"36","author":"Robinson","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0280","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00198-018-04821-7","article-title":"Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France","volume":"30","author":"Hiligsmann","year":"2019","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2023.107846_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10510","article-title":"A prospective open-label observational study of a buffered soluble 70 mg alendronate effervescent tablet on upper gastrointestinal safety and medication errors: the GastroPASS study","volume":"5","author":"Minisola","year":"2021","journal-title":"JBMR Plus"},{"key":"10.1016\/j.maturitas.2023.107846_bb0290","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00198-012-2175-7","article-title":"Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2023.107846_bb0295","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/jcm10010152","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0300","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0305","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0310","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.107846_bb0315","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0320","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0325","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14740338.2018.1430764","article-title":"Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis","volume":"17","author":"Fontalis","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.maturitas.2023.107846_bb0330","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.107846_bb0335","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2023.107846_bb0340","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12020-019-01919-8","article-title":"The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment","volume":"64","author":"Gua\u00f1abens","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.maturitas.2023.107846_bb0345","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.107846_bb0350","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ecl.2021.03.010","article-title":"Update on approved osteoporosis therapies including combination and sequential use of agents","volume":"50","author":"Saul","year":"2021","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.maturitas.2023.107846_bb0355","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2023.107846_bb0360","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0365","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.107846_bb0370","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.107846_bb0375","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0380","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0385","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2023.107846_bb0390","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","article-title":"Romosozumab and antiresorptive treatment: the importance of treatment sequence","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2023.107846_bb0395","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0400","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","article-title":"Risk of subsequent fracture after prior fracture among older women","volume":"30","author":"Balasubramanian","year":"2019","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2023.107846_bb0405","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/jcm11092313","article-title":"Mortality after sustaining skeletal fractures in relation to age","volume":"11","author":"Bergh","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.maturitas.2023.107846_bb0410","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00198-019-05174-5","article-title":"Impact of osteoporotic fracture type and subsequent fracture on mortality: the Troms\u00f8 Study","volume":"31","author":"Alarkawi","year":"2020","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.maturitas.2023.107846_bb0415","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.maturitas.2023.107846_bb0420","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.107846_bb0425","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/13697137.2016.1262840","article-title":"Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions","volume":"20","author":"Palacios","year":"2017","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.107846_bb0430","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/13697137.2015.1107039","article-title":"Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey","volume":"19","author":"Nappi","year":"2016","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.107846_bb0435","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.maturitas.2015.07.020","article-title":"Update on management of genitourinary syndrome of menopause: a practical guide","volume":"82","author":"Palacios","year":"2015","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2023.107846_bb0440","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/13697137.2015.1124259","article-title":"Treating vulvovaginal atrophy\/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?","volume":"19","author":"Edwards","year":"2016","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.107846_bb0445","series-title":"S\u00edndrome Genitourinario de la Menopausia, MenoGu\u00eda AEE","volume":"2020","year":"2020"},{"key":"10.1016\/j.maturitas.2023.107846_bb0450","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/GME.0000000000001221","article-title":"A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause","volume":"26","author":"Biehl","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.107846_bb0455","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society","volume":"27","author":"The NAMS 2020 GSM Position Statement Editorial Panel","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.107846_bb0460","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/GME.0000000000000485","article-title":"Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel","volume":"23","author":"Caruso","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.107846_bb0465","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.maturitas.2021.04.005","article-title":"Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide","volume":"148","author":"Hirschberg","year":"2021","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2023.107846_bb0470","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/GME.0000000000001292","article-title":"Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial","volume":"26","author":"Archer","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.107846_bb0475","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/jwh.2017.6385","article-title":"Overall safety of ospemifene in postmenopausal women from placebo-controlled phase 2 and 3 trials","volume":"27","author":"Simon","year":"2018","journal-title":"J. Women's Health"},{"key":"10.1016\/j.maturitas.2023.107846_bb0480","author":"European Medicines Agency, Senshio"},{"key":"10.1016\/j.maturitas.2023.107846_bb0485","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/13697137.2019.1631789","article-title":"Effects of ospemifene on bone in postmenopausal women","volume":"22","author":"de Villiers","year":"2019","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.107846_bb0490","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"H\u00e4ndel","year":"2023","journal-title":"BMJ"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512223004528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512223004528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:22:53Z","timestamp":1759915373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512223004528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":98,"alternative-id":["S0378512223004528"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2023.107846","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential management of postmenopausal health and osteoporosis: An update","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2023.107846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107846"}}